Dosing and uses of Xalatan (latanoprost)
Adult dosage forms and strengths
ophthalmic solution
- 0.005%
Elevated Intraocular Pressure
1 drop in affected eye qDay in evening
Other Indications & Uses
Open-angle glaucoma
Pediatric dosage forms and strengths
Safety and efficacy not established
Xalatan (latanoprost) adverse (side) effects
>10%
Increase in brown pigmentation of the iris (15.5%)
Blurred vision (5-15%)
Burning and stinging (5-15%)
Foreign body sensation (5-15%)
Itching (5-15%)
Punctate epithelial keratopathy (5-15%)
Conjunctival hyperemia (5-15%)
1-10%
Upper respiratory tract infection/cold/flu (4%)
Dry eye (1-4%)
Excessive tearing (1-4%)
Eye pain (1-4%)
Lid crusting (1-4%)
Lid edema (1-4%)
Lid erythema (1-4%)
Lid discomfort/pain (1-4%)
Photophobia (1-4%)
Chest pain/angina pectoris (1-2%)
Muscle/joint/back pain (1-2%)
Rash/allergic skin reactions (1-2%)
<1%
Conjunctivitis
Diplopia
Discharge from the eye
Frequency not defined
Dizziness
Headache
Warnings
Contraindications
Hypersensitivity to lantanoprost, benzalkonium chloride or other components of product
Pregnancy and lactation
Pregnancy category: C
Lactation: not known whether distributed into milk; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Xalatan (latanoprost)
Absorption: ocular and systemic
Half-Life: 17 min
Vd: 0.36 L/kg
Clearance: 13 mL/min/kg
Metabolism: latanoprost absorbed through the cornea is hydrolyzed to latanoprost acid & does not appear to undergo additional metabolism in ocular tissues; systemically absorbed latanoprost acid is metabolized in the liver by fatty acid ß-oxidation to 1,2-dinor & 1,2,3,4-tetranor metabolites
Excretion: urine
Mechanism of action
Prostaglandin F2-alpha analog; incr outflow of aqueous humor
